Clinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication
NCT01545453 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication
- Lead sponsor
- Genentech, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 31, 2012
- Completion date
- July 31, 2013
- Enrollment
- 205 (actual)
- Sites
- 63
Conditions
As the registry lists them; a condition with its own page is linked.